Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.
Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.
Only 2.6% of the sample were given paxlovid, and they didn’t control for vaccination status.
Also, it only covered 1 month nearly 2 years ago in a single country, and the virus has mutated several times since then.